Company Overview
Hyperion DeFi, Inc. operates as an ophthalmic technology company focused on the development and commercialization of ophthalmic solutions within the United States market. The firm specializes in providing Optejet, a topical ophthalmic medication dispensing platform, and holds a license agreement with Bausch Health Ireland Limited to support its product offerings. This enterprise functions within the Healthcare sector, specifically targeting the Biotechnology industry, where innovation in medical device delivery systems is critical for patient adherence and treatment efficacy. The company's current market capitalization stands at $28.98M, while its trailing twelve-month revenue is recorded at $813,455, and the employee count is listed as N/A. These financial metrics indicate that Hyperion DeFi, Inc. is a micro-cap entity with limited scale relative to established peers, suggesting that its operations are likely concentrated in early-stage commercialization or specific niche product lines rather than broad market penetration. The combination of a sub-$30 million market cap and revenue under $1 million implies significant vulnerability to market fluctuations and a reliance on successful product adoption to achieve substantial growth.
Financial Health
The company reported a trailing twelve-month revenue of $813,455, yet it incurred a net loss of $-46,999,216, resulting in a negative EBITDA of $-17,852,844. The substantial discrepancy between the low revenue figure and the massive net loss reveals a cost structure characterized by high operating expenses or research and development expenditures that far outpace current sales generation. Free cash flow for the period was $-15,670,971, indicating that the company is consuming cash reserves to fund its operations and development activities rather than generating liquidity from its core business. Gross margin stands at 12.9%, suggesting that the cost of goods sold consumes a significant portion of the top line, which is typical for early-stage biotechnology firms with specialized manufacturing requirements. Operating margin is reported at -3690.9% and profit margin at 0.0%, figures that underscore the severe inefficiency or heavy investment phase the company is currently experiencing before achieving profitability. On the balance sheet, the company holds $6.44M in cash against $8.51M in debt, creating a net liability position, while the debt-to-equity ratio of 20.74 highlights a highly leveraged capital structure relative to its equity base. The current ratio of 2.68 indicates that the company possesses sufficient current assets to cover its short-term liabilities more than twice over, providing a buffer for liquidity needs despite the negative cash flow. Return on Equity is -324.1% and Return on Assets is -42.8%, metrics that demonstrate management is currently unable to generate positive returns on the capital invested by shareholders or utilized in the company's assets.
Valuation Assessment
Trailing P/E and forward P/E are both N/A due to the company's lack of earnings, a condition common for pre-revenue or loss-making biotechnology entities where traditional earnings-based valuation multiples cannot be applied. The price-to-book ratio is 0.72, indicating that the market values the company at a discount relative to its net asset value, which may reflect skepticism regarding the recoverability of its intangible assets or future earning potential. The price-to-sales ratio is 35.62, a high multiple that suggests the market is pricing the stock based on future growth expectations rather than current profitability, while the EV/EBITDA stands at -1.78, further emphasizing the reliance on alternative valuation methods given the negative earnings profile. The 52-week high is $17.18 and the 52-week low is $0.85, and without a specific current price provided in the facts, the valuation range demonstrates extreme volatility within the last year. Beta is N/A, meaning that the stock's price volatility relative to the broader market cannot be quantified with the available data.
Growth & Income
Revenue growth year-over-year is reported at 1666.4%, reflecting a massive expansion in sales, whereas earnings growth is N/A because the company continues to report net losses. Since earnings growth is not applicable due to the negative net income, the rapid revenue increase implies that the company is scaling its top line faster than it is managing its bottom line, a typical pattern for growth-stage biotechs investing heavily in expansion. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that any free cash flow generated is reinvested into operations or used to service debt rather than distributed to shareholders. This reinvestment strategy is consistent with a non-dividend payer profile, where capital is directed toward research and development to potentially reach profitability in the future.